CSF2 and dermatomyositis: However, because the impact of tacrolimus' GM-CSF activity-lowering effect on APAP is not well understood, we continued to administer tacrolimus, which is an important therapeutic agent for the management of anti-MDA-5 antibody-positive dermatomyositis.